Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Connelly Robert
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DeMuth Peter
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Haqq Christopher
Elicio Therapeutics | DEF 14A: Definitive information statements
Elicio Therapeutics | ARS: Annual Report to Security Holders
Elicio Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Elicio Therapeutics | 8-K: Current report
Elicio Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Yekaterina Chudnovsky(38.7%),GKCC, LLC(38.7%)
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Chudnovsky Yekaterina
Elicio Therapeutics | 10-Q: Q2 2024 Earnings Report
Elicio Therapeutics | 8-K: Current report
Elicio Therapeutics | 8-K: Current report
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Venkatesan Jay
Elicio Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Yekaterina Chudnovsky(19.99%),GKCC, LLC(19.95%)
Elicio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Chudnovsky Yekaterina
Elicio Therapeutics | 8-K: Current report
Elicio Therapeutics | 424B5: Prospectus
Elicio Therapeutics | 424B5: Prospectus
Elicio Therapeutics | 8-K: Current report
Elicio Therapeutics | EFFECT: Others
No Data
No Data